Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Consolidation in High Risk DLBCL
NCT03463057Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Aug 2018
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of atezolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Started Aug 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03463057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463057.